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Conclusions: We think our program is able to detect large momentary 
MLC errors during VMAT delivery even if DFV can't detect these errors. 
In addition, our program provides many users ease for quality 
assurance of MLC because our program can visualize the MLC motion 
during VMAT delivery.  
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Purpose/Objective: The aim of this study is to evaluate the 
performance of the treatment planning algorithm in the 
determination of dose distributions for non-standard breast cancer 
treatments (arctherapy and Accelerated Partial Breast Irradiation –
APBI-), by means of in-phantom TLD dosimetry. 
Materials and Methods: TLD-100 chips were used to determine the 
absorbed dose at different points in the surface an anthropomorphic 
female thorax phantom, as well as at the center of the simulated 
tumor, inside the lung and at the interface between lung (polystyrene 
foam, ρe=0.19 e/cm3) and tissue (mixture of glycerin and gelatin, 
ρe=1.125 e/cm3). Dose measurements were compared to the results 
obtained with the TPS XiO® V4.62 using the FFT convolution algorithm. 
The APBI treatment included 6 beams of 6 MV, four of which were 
non-coplanar with a mean field size of about 4x4 cm2. The arc 
treatment was performed using 6 beams of 6 MV and one of 15 MV 
beams, 2 of them were arcs. Both treatments were planned using 
forward planning. 
Results: It was found that tumor dose measurements, for arctherapy 
exhibited a mean variation of 5% under the TPS values and of 13% for 
the APBI case. In both treatments the dose at the surface was 
consistently overestimated by the algorithm, 6% in the arctherapy 
case and 18% for the APBI treatment. Lung measurements presented 
larger deviations in both techniques. 
Conclusions: Arctherapy measurements, in general, agreed better 
with the calculated results. This was expected considering the higher 
complexity of the APBI technique. The relatively large deviations 
observed for the tumor can be explained by the reduced size of the 
phantom’s breast, which made difficult to locate the detectors under 
equilibrium conditions and far from high dose gradients. There was a 
marked trend of TPS overestimation of the dose in tissue interphases, 
consistent with the absence of epithelitis in patients treated with 
these techniques. 
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Purpose/Objective: Past incidents in radiotherapy centers both in 
Belgium and in surrounding countries have shown the need for an 
extensive quality audit program in radiotherapy. In Belgium these 
audits were first commissioned by the Federal Agency for Nuclear 
Control (FANC) and performed as a voluntary national audit 
(BELdART). It was the first national audit program using L-α-alanine-
EMR dosimetry at such large scale. All Belgian radiotherapy 
departments participated in the BELdART dosimetry audit over a 
period of 3 years (2009 – 2011). In total 34 centers and 61 linacs were 
audited and were confirmed to work within optimal levels. At the end 
of 2012 the College of Medicine - Radiotherapy gave the permission to 
start with a national mailed audit program involving more complex 
radiation therapy techniques.  
Materials and Methods: All clinical radiation units in Belgium (> 91) 
will be audited in a period of 4 years using 2 independent dosimetric 
techniques. The audit is designed for more complex treatment 
techniques, i.e. IMRT, arc therapy, Tomotherapy, Ciberknife, …. 
Absolute measurements will be performed using L-α-alanine-EMR 
dosimetry and EBT3 film dosimetry will be used for the measurement 
of 2D dose distributions. Irradiations will be performed at the hospital 
centers and the local physicists will perform both planning and 
delivery. The 'easy-cube' (sun nuclear) will be used as phantom and 
custom made slabs preloaded with the alanine pellets and gafchromic 
films will be inserted for the different steps in the QA protocol to 
limit the amount of manipulation involved in the process and reduce 
the user-dependent uncertainty. Beside checks of the treatment 
delivery in homogeneous and inhomogeneous setting an extra check 
where the electron density reconstructed by the treatment planning 
will be compared to the known values of the easy cube. 
Results: The first round of auditing for basic conditions have shown 
that it was possible with alanine to reach an accuracy similar to the 
golden standard ionization chamber with an uncertainty of 1% (k=1) 
for doses down to 4 Gy. Preliminary audits will be performed in 
cooperation with university hospitals in Belgium to assess the realistic 
achievable quality of IMRT implementation in Belgium. 
Conclusions: In view of the development of new techniques of 
radiation dose delivery that brings new difficulties even at the level of 
reference dosimetry, auditing programs using completely independent 
dosimeters are of the utmost importance to insure safe and high 
quality treatments at the national level. 
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Purpose/Objective: The aim of this work is to present a method; 
developed in our hospital, that allows using Gafchromic EBT2 films to 
perform absolute dosimetry. 
Materials and Methods: The method consists of two parts: the first 
one is to perform a dosimetry calibration and the second to apply a 
correction to remove the transverse dependence of the scanner. 
Dosimetry calibration is done following the steps outlined in the paper 
by A. Micke et al.(1) concerning the dual channel calibration (DCC) for 
Gafchromic EBT2 films irradiated at different dose levels ?? in a 
Siemens ARTISTE linac and digitized in transmission mode 24 hours 
after irradiation using an Epson Expression 10000XL scanner. Each film 
is digitized three times placing it in the center of the scanner with 
landscape orientation and active layer down. In each digital image 
RGB channels are splitted using ImageJ software. Pixel value (PV) is 
converted into optical density (OD) for the red (ODr) and blue (ODb) 
channels. A new image is obtained dividing the ODr image (ODrI) by 
ODbI. This process is done with an ImageJ plug-in developed by the 
authors of this work. Dose (D) readings are made with PTW 0.6 cc 
ionization chamber (IC), placed in a RW3 slabs phantom. Obtaining the 
average value ODr/ODbin a ROI centered on each image the 
calibration table {ODr/ODb, D} is generated. Transverse correction is 
obtained digitizing the pieces of film used in the DCC. Pieces are 
placed at different lateral positions along the center of the scanner 
and 112 images are obtained (14 positions x 8 dose levels). Red 
channel is splitted from each image and a set of 112 readouts is 
generated getting the PVr from 1x1 cmxcm centered ROI's normalized 
to that of the center of the scanner. Correction factor, f(x, D) is 
obtained as a function of the lateral position (x) and D. 
Results: It is noted that dose dependence of the correction factor is 
negligible thus a new factor is calculated based on the average: f (x). 
Plotting f(x) versus x (# pixel), three differentiated regions are 
observed (Fig 1). 
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 Our adjusted correlation factor is: 
 
 To obtain the calibrated image, the PVrI is divided by this factor, 
converted into ODrI, divided by ODbI and finally DCC is applied. 
Conclusions: This method was applied for several beam configurations 
placing EBT2 films in different phantoms. Dose planes obtained were 
compared to equivalent measures obtained with PTW 2D-ARRAY 
seven29 and to calculated data from CMS XiO TPS. PTW Verisoft was 
used to calculate Gamma2D planes and in all cases the gamma index 
(3%, 3 mm) was below 1 for at least 95% of points. There is also a good 
agreement between the absolute doses measured at different points 
of the film with measurements made with IC. Differences are less than 
3%. 
REF. (1) A. Micke, D. Lewis and X. Yu, 'Multichannel film dosimetry with 
nonuniformity correction', Med. Phys. 38(5), 2523-2534, (2011). 
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Purpose/Objective: Pre-treatment verification of radiation plans is an 
important part of the quality assurance program. None of advanced 
treatment techniques could be applied without the guarantee that the 
delivered dose is coincided with the planning dose at a level of the 
IAEA recommendations. This analysis can be performed by the means 
of the electronic portal imaging device (EPID). The method of the 3D 
dosimetric verification of the volumetric-modulated arc therapy 
(VMAT) plans based on EPID was studied. 
Materials and Methods: It was investigated about 50 radiation 
treatment plans for the SBRT patients with non-small cell lung cancer 
(NSCLC), pulmonary metastasis, prostate cancer, head-and-neck 
tumors and brain lesions, which were treated in the Centre for 
Stereotactic Radiotherapy and Radiosurgery in Novosibirsk Research 
Institute for Circulation Pathology. During a complete treatment 
simulation at the linac the portal dose images (PDI) were received for 
each patient field and compared with the planned PDIs. 3D dosimetric 
verification was performed for all patient plans calculated according 
with the volumetric-modulated arc therapy (VMAT). The procedure 
fulfilled using the IViewGT electronic portal imaging device (EPID) and 
Dosimetry Check software. The plans were verified by comparison the 
isodose lines, 2D profiles, dose volume histograms and γ-analysis. 
Results: The planned and reconstructed dose distributions showed 
good agreement for pre-treatment verification of the VMAT plans. The 
average planned and measured isocentre dose difference was 1.20% 
(range 0.07–2.56%). 3D γ-analysis revealed γmean= 0.28 for lung 
metastasis, 0.32 for lung SBRT, 0.33 for prostate, 0.33 for brain 
lesions and 0.39 for head-and-neck tumors. The passing criteria for 
the treatment plans was established for the head-and-neck tumors 
within P% = 90% (γ ≤ 1) and within P% = 95% (γ ≤ 1) for other considered 
localizations. 
Conclusions: Verification method on the base of electronic portal 
imaging device has been successfully implemented. EPID can be used 
for the high accuracy, high resolution and fast routine pre-treatment 
verification of VMAT treatment plans.  
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Purpose/Objective: The purpose of this study was to evaluate an 
absolute pre-treatment verification method for Cyberknife therapy 
with a PinPoint ionization chamber and radiochromic EBT3 films. 
Materials and Methods: The CT scan of the Easy cube Phantom was 
acquired with the clinical parameters used for Cyberknife patients; 
the PinPoint ionization chamber and radiochromic film were 
positioned in the centre of the phantom. Eight fiducial markers were 
previously inserted into the phantom for treatment set-up. A fiducial 
tracking method was used for template QA plan: the patient’s plan 
was recalculated on the Easy Cube phantom and centred in the 
sensitive volume of the Pin Point ionization chamber. The dose was 
calculated with Ray-Tracing algorithm. The radiochromic EBT3 films 
were properly calibrated with a 6 MV linear accelerator (Clinac 600, 
Varian), delivering dose from 0 Gy to 10 Gy with 12 dose points. A 
total of 137 patients were evaluated: 91 patients with the PinPoint 
chamber only and 46 patients with PinPoint chamber and radiochromic 
film.  
Absolute dose measured with the PinPoint chamber was compared 
with the mean dose calculated in the sensitive volume of the chamber 
from the treatment planning system. The radiochromic films were 
scanned using a Epson 1000XL in transmission mode, 48 bit colour and 
resolution of 72 dpi. For each patient, calculated and measured axial 
planar dose distribution was compared with the Gamma Analysis 
Method (3% dose difference and 3 mm distance to agreement criteria) 
performed by the VeriSoft Program (PTW). 
Results: The percentage differences between calculated and 
measured PinPoint absolute dose ranges from -7.2 to 9.1 with a mean 
value of 4.8±4.1, resulting to be below 5% in the 73.9% of cases. The 
percentage of patients passing the gamma analysis (90% of pixels 
exceeding a 3% and 3 mm threshold) was 84.8%. 
Conclusions: The results obtained with PinPoint measurements show a 
good agreement between calculated and measured absolute dose. 
Preliminary results obtained with radiochromic films show some 
critical aspects. Further investigations regarding the possible 
employment of a 2D-array are required in order to perform the 
comparison between calculated and measured axial planar dose 
distribution with the possibility to speed up the procedures of QA 
program. 
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Purpose/Objective: The DAVID is an optically-transparent, 
transmission-style detector composed of two sheets of Perspex 
enclosing a vented air gap. The gap contains a series of collection 
wires running in the direction of the MLC leaf movement; each wire is 
held at a potential and is aligned with an individual MLC leaf pair. The 
signal generated at each wire is proportional to the radiation fluence 
through its associated leaf pair; with additional components from 
adjacent leaf apertures, due to scatter inside the Perspex. The 
current paradigm for using the DAVID, as an in-vivo device, is to 
record a DAVID signal during the pre-treatment verification of 
treatment delivery to a phantom; should the treatment pass the 
verification, the DAVID signal will be used as a baseline to compare 
the subsequent in-vivo responses for each treatment fraction. A new 
procedure has been suggested, where the treatment is verified using 
independent checking software; if the treatment passes this test, the 
information held by the independent software is then used to 
generate a DAVID signal, which can be used as a baseline for the 
subsequent in-vivo measurements. The independent dose check and 
generation of a baseline signal for in-vivo measurements provides a 
safe system that will catch errors in the TPS, plan transfer to the 
